Efficacy and Safety of Indobufen and Clopidogrel in Patients with Ischemic Cardiovascular and Cerebrovascular Diseases Combined with Upper Gastrointestinal Hemorrhage
Objective:To analyze the effect and safety of Indobufen and Clopidogrel in patients with ischemic cardiovascular and cerebrovascular disease combined with upper gastrointestinal hemorrhage.Method:Sixty patients with ischemic cardiovascular and cerebrovascular diseases combined with upper gastrointestinal hemorrhage admitted to Chaozhou Central Hospital from March 2021 to April 2023 were selected,and they were randomly divided into two groups,30 cases in each group.The control group treated with Clopidogrel and the observation group treated with Indobufen.The clinical efficacy,inflammatory factors and adverse reactions of the two groups were compared.Result:After the intervention,the overall response rate in the observation group was 96.67%(29/30),which was higher than 76.67%(23/30)in the control group,the difference was statistically significant(P＜0.05).After the intervention,the hypersensitive C-reactive protein(hs-CRP),procalcitonin(PCT)in the observation group were significantly lower than those in the control group,the differences were statistically significant(P＜0.05).The incidence of adverse reactions in the observation group was 6.67%(2/30),which was lower than 26.67%(8/30)in the control group,the difference was statistically significant(P＜0.05).Conclusion:Compared with Clopidogrel,Indobufen has good efficacy in patients with ischemic cardiovascular and cerebrovascular diseases combined with upper gastrointestinal hemorrhage,effectively improves the level of inflammatory factors and reduces the incidence of adverse reactions,has better safety.
IndobufenClopidogrelIschemic cardiovascular and cerebrovascular diseaseUpper gastrointestinal hemorrhageSafety
国家科技期刊平台
NSTL
万方数据
